Pregabalin Toxicity-Induced Posterior Reversible Encephalopathy Syndrome
- Authors
-
-
Dr.Rania AMMAR ZAYANI
university of sfax faculty of medecine of sfax
-
Dr.Sarra Temani
university of Sfax, faculty of medecine of sfax
-
Dr. Mabrouk Bahloul
university of Ufax, faculty of medecine of sfax
-
Dr.Chokri Ben Hamida
university of Sfax, faculty of medecine of sfax
-
- Abstract
-
Posterior reversible encephalopathy syndrome (PRES) is a neurological phenomenon in which vasogenic edema most commonly accumulates in the posterior parieto-occipital white matter[1]. It was caused by some drugs such as opioids [2,3] methadone [4] or gabapentin [5]. Rare cases of PRES-related pregabalin were reported [6,7]. It was typically used to treat neuropathic pain [4]. We present a unique case of a 23-year-old patient without any previous history admitted to intensive care for quadriplegic paralysis with Guillain-Barre syndrome. His neuropathic pain was treated with pregabalin. He presented poorly balanced hypertension and a worsening of renal function due to colistin toxicity. On day 52, he presented a sudden drop in visual acuity without altering his consciousness. Cerebral MRI revealed subcortical white matter edema in the bilateral parietal and occipital lobes with T2 and Flair hyper signals without diffusion restriction suggestive of PRES. He was treated by controlling hypertension and by stopping pregabalin. The clinical course was favorable after 5 days, with a recovery of visual acuity. This case indicates that physicians must be aware of potential PRES-related Pregabalin toxicity especially when increasing its doses in patients presenting worsening of renal function and in association with opioids.
- Author Biographies
- References
- Downloads
- Published
- 30-06-2025
- Section
- Case Reports
- License
-
Copyright (c) 2025 Tunisian Journal of Emergency Medicine

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
THE tjem allows authors to retain unrestricted copyright and full publishing rights of their articles.
All articles published in this journal are openly accessible and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This guarantees that anyone is free to:
-
Share: Copy and redistribute the material in any medium or format.
-
Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
Under the following terms:
-
Attribution: Users must give appropriate credit to the original author(s) and the journal, provide a link to the license, and indicate if changes were made.
By submitting a manuscript to tjem, authors grant the journal the right of first publication, while retaining full ownership of their intellectual property.
-
